Gilead Sizes Biktarvy's Medicare Price Hit At About $1.5 Billion In 2028 — And Attacks The 'Pill Penalty'
CEO Daniel O'Day says the government's price ignores Biktarvy's value, while the CFO still expects 2028 earnings per share to grow.
Gilead Sciences expects the Medicare price set for its HIV drug Biktarvy to cut about $1.5 billion from the drug's net revenue in 2028, Chief Financial Officer Andrew Dickinson said on the company's third-quarter earnings call Thursday. Chairman and CEO Daniel O'Day said the price "does not reflect the value of Bictarvy."
A $2,600 price and a $1.5 billion hit
Dickinson said the Centers for Medicare and Medicaid Services set Biktarvy at $2,600 per 30-day supply, an approximate 38% discount from the list price in the Medicare channel. Based on a preliminary analysis, he expects Biktarvy revenue to fall in 2028 from 2027.
The $1.5 billion covers the lower Medicare price plus knock-on effects in other U.S. channels, including Medicaid, 340B and other payers. Asked by a Jefferies analyst for the split, Chief Commercial and Corporate Affairs Officer Johanna Mercier said it is "primarily Medicare," with spillover to other channels, and that it is too early for more detail. She said the figure is net of the Part D redesign impact Biktarvy absorbed in 2025, which goes away in 2028.
Dickinson still expects total HIV revenue, total product sales and earnings per share to grow in 2028 versus 2027, citing other HIV innovations and growth in oncology and inflammation. He said those statements rest on current assumptions, and formal guidance will come in early 2028.
O'Day's case against the "pill penalty"
O'Day said price-setting under the Inflation Reduction Act puts investment in new medicines at risk, especially for differentiated drugs in the middle of their lifecycle. Some diseases, HIV among them, can only be addressed by small-molecule medicines, he said, and the "pill penalty" now applied to Biktarvy discourages investment in them.
"We firmly oppose policies like this that undermine innovation," O'Day said. He added that the business is strong and built to respond to such headwinds.
A record quarter behind the warning
Gilead, which develops medicines for HIV, viral hepatitis, COVID-19 and cancer, said base business sales rose 16% from a year earlier to $8.2 billion in the third quarter. Total product sales were $8.3 billion, up 13%. Non-GAAP earnings per share were $2.55, against $2.47 a year earlier.
HIV sales rose 18% to $6.2 billion. Biktarvy sales were $4.1 billion, up 10%, and its U.S. treatment market share hit an all-time high of 53%, Mercier said.
Dickinson pointed to earlier policy hits Gilead has absorbed: a $1.1 billion headwind from Medicare Part D redesign in 2025 and one above $500 million from the Affordable Care Act and other government policies in 2026. With more than a year before the new Biktarvy price takes effect, he said, the company will work to mitigate some of the impact. Mercier said the company has about a year to do so.
Gilead now expects 2026 base business sales of $30.7 billion to $31 billion, and it plans to give formal 2028 guidance in early 2028.
Sources
- Gilead Stock Hits Record High; Notches Best Sales Growth In A Decade | Investor's Business Daily — investors.com
- Gilead Sciences Non-GAAP EPS of $2.55 beats by $0.36, revenue of $8.3B beats by $500M (NASDAQ:GILD) | Seeking Alpha — seekingalpha.com
- Gilead: Q3 Earnings Snapshot — Associated Press
- Gilead Sciences Announces Third Quarter 2026 Financial Results – Company Announcement - FT.com — Financial Times
- 3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead — Yahoo Finance